CliniLabs Completes FDA Inspection With No Findings

• CliniLabs LLC successfully completed a routine FDA inspection with no observations or findings.

• The outcome reflects the CRO’s quality systems, regulatory compliance, and operational standards across clinical research programs. 

CliniLabs LLC announced it has successfully completed a routine inspection by the U.S. Food and Drug Administration (FDA) with no observations. The company said the outcome reflects its adherence to regulatory standards across its clinical research operations as a global contract research organization (CRO) focused on CNS drug and device development. 

The FDA inspection reviewed multiple aspects of CliniLabs’ clinical operations, including data integrity, regulatory compliance, and adherence to study protocols. According to the company, the absence of findings demonstrates the strength of its quality systems and its ability to operate within highly regulated clinical environments. 

CliniLabs provides full-service CRO capabilities supporting Phase 1 through Phase 4 clinical trials, with a focus on central nervous system disorders. The company indicated that quality and compliance are embedded across its clinical operations, including data management, regulatory oversight, and patient engagement. 

The inspection outcome comes as regulatory scrutiny remains high across the CRO sector, where sponsors rely on service providers to ensure data quality, patient safety, and compliance with global standards. A clean FDA inspection is often viewed as a validation of operational processes and internal quality controls.

“Each FDA inspection is an opportunity…commitment to data integrity.” 

Gary Zammit, President and Chief Executive Officer of CliniLabs